Bronchodilator efficacy of indacaterol, a novel once-daily β2-agonist, in patients with persistent asthma

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 1, 2008, Pages 90-95

  Pearlman, David S ^a,e   Greos, Leon ^a   LaForce, Craig ^b   Orevillo, Chadwick J ^c   Owen, Roger ^d   Higgins, Mark ^d  

^a Respiratory Institute   (United States)

^b North Carolina Clinical Research   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^e Rampart Campus ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; INDACATEROL; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NERVOUSNESS; POTASSIUM BLOOD LEVEL; POWDER INHALER; PRIORITY JOURNAL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; SIDE EFFECT; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; SYNCOPE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 47349093973     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60840-X     Document Type: Article

References (15)

1. National Heart, Lung, and Blood Institute National Asthma Eduration and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 07-4051. Originally printed July 1997. Revised June 2002, August 2007. http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.pdf. Accessed February 1, 2007.
2. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: NIH; 2006. NIH publication 02-3659.
3. 2-agonist, provides sustained 24-hour bronchodilation in asthma. Eur Respir J. 2007;29:871-878.
4. Chuchalin AG, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med. 2007;101:2065-2075.
5. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Bethesda, MD: NIH; 2003. NIH publication 02-3659.
6. Crapo RO, Morris AH, Gardner RM. Reference Spirometrie values using techniques and equipment that meet the ATS recommendation. Am Rev Respir Dis. 1981;123:659-664.
7. Morganroth J. Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clin Pharmacol Ther. 2007;81:108-113.
8. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry. E14 Clinical evaluation of QT/QTc interval prolongation and proarhythmic potential for non-antiarrhythmic drugs. October 2005. http://www.fda.gov/cder/guidance/index.htm. Accessed February 1, 2007.
9. Kanniess F, Cameron R, Owen R, Higgins M. Indacaterol, a novel 24-hour β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Respir J 2005;26(suppl 49):253s, P1729.
10. 2-agonist, is well tolerated in patients with asthma: a randomized, placebo-controlled 28-day safety study. Ann Allergy Asthma Immunol. 2007;99:555-561.
11. LaForce C, Alexander M, Deckelmann R, et al. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day, dose-ranging study. Allergy. 2008;63:103-111.
12. Krummen M, Kahli D, Hoerbing S, et al. Flow-rate dependency of the fine particle fraction and the uniformity of the delivered dose of several commercial formoterol dry powder inhalers [abstract]. J Aerosol Med 2006;19:221-241.
13. Krummen M, Singh D, Fiebich K, Haeberlin B. Flow-dependent performance of several formoterol dry powder inhalers (DPIs) [abstract]. Eur Respir J. 2006(suppl):435s.
14. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2007; In press.
15. Ahrens RC. On comparing inhaled beta adrenergic agonists. Ann Allergy. 1991;67:296-298.